1 / 23

Key HIV Research From ICAAC 2007: Complications of HIV/HAART

Key HIV Research From ICAAC 2007: Complications of HIV/HAART. Faculty:. Chicago, Illinois | September 17-20, 2007. Cal Cohen, M.D., M.S. Eric Daar, M.D. This activity is supported by an educational grant from:. Faculty for This Activity.

teva
Télécharger la présentation

Key HIV Research From ICAAC 2007: Complications of HIV/HAART

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Key HIV Research From ICAAC 2007: Complications of HIV/HAART Faculty: Chicago, Illinois | September 17-20, 2007 Cal Cohen, M.D., M.S. Eric Daar, M.D. This activity is supported by an educational grant from:

  2. Faculty for This Activity Dr. Cohen is the research director of the Community Research Initiative of New England and teaches at Harvard Medical School in Boston, Mass. In addition, he works as a HIV clinical management consultant and internist at Harvard Pilgrim Health Care, Boston, Mass., and is affiliated with Harvard Vanguard Medical Associates. Dr. Cohen was co-chair of the Scientific Advisory Committee of amfAR community-based clinical trials network, and served as co-principal investigator of the Harvard/BCH AIDS Clinical Trials Unit, AIDS Clinical Trials Group. He holds appointments at Brigham and Women's Hospital and Beth Israel Hospital, both in Boston, Mass. Cal Cohen, M.D., M.S. Dr. Daar is the chief of HIV medicine at Harbor-UCLA Medical Center in Los Angeles, Calif., and a professor of medicine at the University of California-Los Angeles' David Geffen School of Medicine. He has been an active HIV physician and researcher since the 1980s; during the past three decades, he has led dozens of studies on a vast range of HIV-related issues, with a particular focus on coinfections and other health complications associated with HIV and HIV treatment, including hepatitis C, metabolic complications, cardiovascular disease and psychosocial issues such as depression. Eric Daar, M.D.

  3. ICAAC 2007: Key HIV Research About this slide presentation • This presentation is one of three slide sets created to accompany The Body PRO's podcast summary of key research presented at ICAAC 2007, featuring interviews with Cal Cohen, M.D., M.S., and Eric Daar, M.D. To download the remaining slide sets or learn more about this, please visit us on the Web at: TheBodyPRO.com/ICAAC2007 • Please feel free to use this slide presentation for personal reference or for your own presentations; however, we ask that you not modify any aspects of the slides contained within this presentation, so proper attribution can be retained. If you would like to publish all or part of this presentation, or repost any of these slides online, permission must first be obtained from Body Health Resources Corporation. • Our gratitude goes out to all who granted permission for their slides to be adapted for this presentation. Disclaimer Knowledge about HIV changes rapidly. Note the date of this presentation's publication, and before treating patients or employing any therapies described in these materials, verify all information independently. If you are a patient, please consult a doctor or other medical professional before acting on any of the information presented in this presentation.

  4. HIV Drug Resistance and the Complications of HIV/HAART

  5. TITAN: Development of Primary Protease Inhibitor Mutations and NRTI Resistance-Associated Mutations Upon Virologic Failure Simon F. De Meyer et al. ICAAC 2007; abstract H-1020. Reprinted with permission.

  6. TITAN: Loss of Susceptibility to Antiretrovirals in Virologic Failures (VFs) upon VF Simon F. De Meyer et al. ICAAC 2007; abstract H-1020. Reprinted with permission.

  7. Genotypic Results and Virological Response After Interruption of NNRTI-Based Treatment Adapted from Somnuek Sungkanuparph et al. ICAAC 2007; abstract H-368.

  8. Change in cGFR: Abacavir (ABC) vs Tenofovir (TDF) Christopher Polk et al. ICAAC 2007; abstract H-383. Reprinted with permission.

  9. Changes in Renal Function Among 10 Patients Categorized as Having “Current Renal Dysfunction” With Both Baseline and 12-Month Values, HIV Outpatient Study, November 2001 – September 2005 Benjamin Young et al. ICAAC 2007; abstract H-382. Reprinted with permission.

  10. ACTG 5102: Lipid Metabolism Pablo Tebas et al. ICAAC 2007; abstract H-378. Reprinted with permission.

  11. ACTG 5102: Changes in Immune Activation Pablo Tebas et al. ICAAC 2007; abstract H-378. Reprinted with permission.

  12. CPCRA 060: Time to CD4 < 350 cells/µL, Therapy Initiation or Death Matthew B. Goetz et al. ICAAC 2007; abstract H-1027. Reprinted with permission.

  13. Comparison of Luciferase Activity (RLUs) Between Standard and Enhanced Trofile Assays Jacqueline D. Reeves et al. ICAAC 2007; abstract H-1026. Reprinted with permission.

  14. Sensitivity to Detect Minor CXCR4-Using Subpopulations Jacqueline D. Reeves et al. ICAAC 2007; abstract H-1026. Reprinted with permission.

  15. V3 Loop Sequence-Based CRT Prediction Results Eric W. Stawiski et al. ICAAC 2007; abstract H-1028. Reprinted with permission.

  16. Description of the Most Frequent Non-AIDS, Non-HAART Related (NANHR) Severe Clinical Events Tristan Ferry et al. ICAAC 2007; abstract H-1722. Reprinted with permission.

  17. Factors Associated With the Occurrence of the 385 First NANHR Severe Clinical Events Tristan Ferry et al. ICAAC 2007; abstract H-1722. Reprinted with permission.

  18. Incidence Rate Ratios (IRR) of Non-AIDS-Defining Malignancies (non-ADM) in HIV-Infected vs. Non-Infected Veterans in the HAART Era Total of 33,420 HIV+ and 66,840 HIV- veterans followed. Incidence rates of non-ADM per 100,000 person-years were 1,260 and 841 respectively. Adapted from Roger J. Bedimo et al. ICAAC 2007; abstract H-1721.

  19. Re-treatment With Pegylated Interferon Plus Weight-Adjusted Ribavirin in HIV+ Patients With Chronic HCV Results Eugenia Vispo et al. ICAAC 2007; abstract H-1734. Reprinted with permission.

  20. Three-Year Survival Data of Liver Transplant Recipients in Spain Years After Transplant 1 2 3 Hepatitis C Monoinfected Patients* 81% (78%-83%) 74% (70%-76%) 69% (65%-72%) HIV/Hepatitis C Coinfected Patients* 88% (74%-94%) 75% (58%-86%) 64% (43%-79%) Twelve (24%) HIV/hepatitis C coinfected and 273 (23%) hepatitis C monoinfected patients died during a median follow-up of 1.3 (0.5-2.4) years. *95% confidence intervals Adapted from José M. Miró et al. ICAAC 2007; abstract H-1732.

  21. PROVE1: Study Design Additional Weeks and Doses Weeks 1-12 Analysis performed when all patients completed 12 weeks.Samples were collected for sequencing at baseline and at each HCV RNA assessment. Adapted from Mark Sulkowski et al. ICAAC 2007; abstract V-1383.

  22. PROVE1 Study Results: Undetectable HCV RNA All Group Results, Weeks 4 and 12 Note: Of those in groups 1-3* receiving 12 weeks of treatment, six of nine subjects with rapid virological response had undetectable HCV RNA 20 weeks after termination of treatment. * Groups 1-3 were taking telaprevir (TVR, VX-950) with peginterferon alfa-2A and ribavirin (RBV). Adapted from Mark Sulkowski et al. ICAAC 2007; abstract V-1383.

  23. ICAAC 2007: Key HIV Research • Visit The Body PRO for Comprehensive Coverage of ICAAC 2007.This presentation is one of three slide sets created to accompany The Body PRO's CME/CE podcast summary of key research presented at ICAAC 2007, featuring interviews with Cal Cohen, M.D., M.S., and Eric Daar, M.D. To download the remaining slide sets or learn more about this CME/CE program, please visit us on the Web at: TheBodyPRO.com/ICAAC2007 • In addition, be sure to browse through The Body PRO’s extensive coverage of ICAAC 2007, which includes: • Downloadable MP3s and full transcripts • Expert discussion of key research • Slides and in-depth data analyses • Visit TheBodyPRO.com/ICAAC2007today for a full listing of our conference materials!

More Related